Article Sidebar
Main Article Content
Terlipressin-Induced Skin Necrosis in 3 Cases: Should We Concern?
Main Article Content
Abstract
Cite this article as: Küçükdemirci Ö, Bektaş A. Terlipressin-induced skin necrosis of 3 cases: should we concern? Turk J Gastroenterol. 2025;36(3):193-196.
Article Details
References
1. Allegretti AS, Subramanian RM, Francoz C, Olson JC, Cárdenas A. Respiratory events with terlipressin and albumin in hepatorenal syndrome: a review and clinical guidance. Liver Int. 2022;42(10):2124-2130. [CrossRef]
2. Cavallin M, Piano S, Romano A, et al. Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: a randomized controlled study. Hepatology. 2016;63(3):983-992. [CrossRef]
3. Zhou Y, Zeng J, Song L, Wang C. Clinical characteristics and treatment of terlipressin-induced ischemic skin necrosis: a synthesis of 35 literature reported cases. J Clin Pharm Ther. 2022;47(8):1270-1275. [CrossRef]
4. Kulkarni AV, Arab JP, Premkumar M, et al. Terlipressin has stood the test of time: clinical overview in 2020 and future perspectives. Liver Int. 2020;40(12):2888-2905. [CrossRef]
5. Küçükdemirci Ö, Gönen Şentürk SG, Eruzun H, Ustaoğlu M, Avcıoğlu U. Ischemic skin necrosis due to terlipressin use in a patient with hepatorenal syndrome: a case report. Gastroenterol Nurs. 2023;46(5):411-415. [CrossRef]